Hunan Er-Kang Pharmaceutical Co., Ltd signed equity purchase agreement to acquire Henan Yuxingkang Pharmaceutical Co., Ltd. from Shuai Fangwen and Cao Zaiyun for CNY 44 million.
October 27, 2021
Share
Hunan Er-Kang Pharmaceutical Co., Ltd (SZSE:300267) signed equity purchase agreement to acquire Henan Yuxingkang Pharmaceutical Co., Ltd. from Shuai Fangwen and Cao Zaiyun for CNY 44 million on October 26, 2021. As per the transaction, Hunan Er-Kang Pharmaceutical Co., Ltd will acquire 80% stake from Shuai Fangwen and 20% stake from Cao Zaiyun in Henan Yuxingkang Pharmaceutical Co., Ltd. Hunan Er-Kang Pharmaceutical Co., Ltd will use its own funds to finance the transaction. As on September 30, 2021, Henan Yuxingkang Pharmaceutical Co., Ltd. generated total assets of CNY 91.1 million and owner?s equity of CNY 44.5 million. The transaction is approved by board of directors of Hunan Er-Kang Pharmaceutical Co., Ltd.
HUNAN ER-KANG PHARMACEUTICAL CO., LTD. is principally engaged in the research, development, production and sales of pharmaceutical excipients, finished drugs and bulk drugs. The Companyâs pharmaceutical excipients mainly consist of glycerol for medicine, sugar for medicine, ethanol for medicine, propylene glycol for medicine, as well as sodium hydroxide for medicine and others. Its bulk drugs consist of sulfadiazine, sulphaguanidine and resorcinol, among others. Its finished drugs consist of sulbenicillin sodium injections and compound liquorice tablets. The Company distributes its products in domestic market and to overseas markets.
Hunan Er-Kang Pharmaceutical Co., Ltd signed equity purchase agreement to acquire Henan Yuxingkang Pharmaceutical Co., Ltd. from Shuai Fangwen and Cao Zaiyun for CNY 44 million.
HUNAN ER-KANG PHARMACEUTICAL CO., LTD 
